Abstract
Background: Progressive proteinuria and glomerulosclerosis characterize chronic allograft nephropathy. However, the causes are not fully elucidated. Podocytes function to prevent proteinuria; injury to this glomerular cell leads to glomerulosclerosis. The potential role of podocytes in the failing transplanted kidney is unknown. A rat model of kidney transplantation, characterized by proteinuria and glomerulosclerosis, was utilized to examine the potential role of podocytes. Methods: Archival tissue was examined from allografts (Dark Agouti kidneys transplanted into operationally tolerant Albino Surgery rats), isografts (Dark Agouti) and controls (Dark Agouti: age-matched or after unilateral nephrectomy). The number of podocytes (by WT-1 staining) as well as the podocyte proteins podocin, nephrin and synaptopodin (by immunostaining) were measured at days 0, 2, 6 and at 6 months after transplantation. Changes in these parameters were compared between groups and correlated with urinary protein excretion. Results: At 6 months, podocyte number was reduced in allografted kidneys, accompanied by a decrease in nephrin and synaptopodin, but not podocin staining. Remnant kidneys in the uninephrectomized rats also showed a decreased podocyte number but no change in podocyte protein staining. Podocyte loss in allografts was established on day 6, whereas a decrease in nephrin and synaptopodin was not evident until 6 months. In contrast, podocyte number and protein staining was decreased but not significantly so in remnant and isografted kidneys. Conclusion: A decrease in the slit diaphragm proteins, nephrin and synaptopodin, is a component of chronic allograft pathology.
Journal Section:
Original Paper
References
1.
Meier-Kriesche HU, Schold JD, Kaplan B: Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004;4:1289–1295.
[PubMed]
2.
Solez K, Colvin RB, Racusen LC, Sis B, Halloran PF, Birk PE, et al: Banff ’05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy Am J Transplant 2007;7:518–526.
3.
Mauiyyedi S, Crespo M, Collins AB, Schneeberger EE, Pascual MA, Saidman SL, et al: Acute humoral rejection in kidney transplantation. II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002;13:779–787.
[PubMed]
4.
Mauiyyedi S, Pelle PD, Saidman S, Collins AB, Pascual M, Tolkoff-Rubin NE, et al: Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001;12:574–582.
[PubMed]
5.
Couser W: Recurrent glomerulonephritis in the renal allograft: an update of selected areas. Exp Clin Transplant 2005;3:283–288.
[PubMed]
6.
Shankland SJ: The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006;69:2131–2147.
[PubMed]
7.
Mundel P, Shankland SJ: Podocyte biology and response to injury. J Am Soc Nephrol 2002;13:3005–3015.
[PubMed]
8.
Kriz W, Elger M, Hosser H, Hähnel B, Provoost A, Kränzlin B, Gretz N: How does podocyte damage result in tubular damage? Kidney Blood Press Res 1999;22:26–36.
[PubMed]
9.
Kriz W, Gretz N, Lemley KV: Progression of glomerular diseases: Is the podocyte the culprit? Kidney Int 1998;54:687–697.
[PubMed]
10.
Ruotsalainen V, Ljungberg P, Wartiovaara J, Lenkkeri U, Kestilä M, Jalanko H, et al: Nephrin is specifically located at the slit diaphragm of glomerular podocytes. Proc Natl Acad Sci USA 1999;96:7962–7967.
[PubMed]
11.
Schwarz K, Simons M, Reiser J, Saleem MA, Faul C, Kriz W, et al: Podocin, a raft-associated component of the glomerular slit diaphragm, interacts with CD2AP and nephrin. J Clin Invest 2001;108:1621–1629.
[PubMed]
12.
Saleem MA, Ni L, Witherden I, Tryggvason K, Ruotsalainen V, Mundel P, Mathieson PW: Co-localization of nephrin, podocin, and the actin cytoskeleton: evidence for a role in podocyte foot process formation. Am J Pathol 2002;161:1459–1466.
[PubMed]
13.
Nakatsue T, Koike H, Han GD, Suzuki K, Miyauchi N, Yuan H, et al: Nephrin and podocin dissociate at the onset of proteinuria in experimental membranous nephropathy. Kidney Int 2005;67:2239–2253.
[PubMed]
14.
Hosoyamada M, Yan K, Nishibori Y, Takiue Y, Kudo A, Kawakami H, et al: Nephrin and podocin expression around the onset of puromycin aminonucleoside nephrosis. J Pharmacol Sci 2005;97:234–241.
[PubMed]
15.
Roth SU, Sommer C, Mundel P, Kiessling M: Expression of synaptopodin, an actin-associated protein, in the rat hippocampus after limbic epilepsy. Brain Pathol 2001;11:169–181.
[PubMed]
16.
Mundel P, Heid HW, Mundel TM, Krüger M, Reiser J, Kriz W: Synaptopodin: an actin-associated protein in telencephalic dendrites and renal podocytes. J Cell Biol 1997;139:193–204.
[PubMed]
17.
Asanuma K, Kim K, Oh J, Giardino L, Chabanis S, Faul C, et al: Synaptopodin regulates the actin-bundling activity of α-actinin in an isoform-specific manner. J Clin Invest 2005;115:1188–1198.
[PubMed]
18.
Siu B, Saha J, Smoyer WE, Sullivan KA, Brosius FC: Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment. BMC Nephrol 2006;7:6.
[PubMed]
19.
Macconi D, Bonomelli M, Benigni A, Plati T, Sangalli F, Longaretti L, et al: Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. Am J Pathol 2006;168:42–54.
[PubMed]
20.
Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, et al: Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005;16:2941–2952.
[PubMed]
21.
Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG, et al: Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997;99:342–348.
[PubMed]
22.
Kretzler M: Role of podocytes in focal sclerosis: defining the point of no return. J Am Soc Nephrol 2005;16:2830–2832.
[PubMed]
23.
Kim YH, Goyal M, Kurnit D, Wharram B, Wiggins J, Holzman L, et al: Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 2001;60:957–968.
[PubMed]
24.
Nankivell BJ, Borrows RJ, Fung CLS, O’Connell PJ, Allen RDM, Chapman JR: Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 2004;78:461–468.
[PubMed]
25.
Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RDM, Chapman JR: Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004;78:242–249.
[PubMed]
26.
Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RDM, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326–2333.
[PubMed]
27.
Coulson MT, Jablonski P, Howden BO, Thomson NM, Stein AN: Beyond operational tolerance: effect of ischemic injury on development of chronic damage in renal grafts. Transplantation 2005;80:353–361.
[PubMed]
28.
Jablonski P, Baxter K, Howden BO, Thomas AC, Marshall VC, Stein-Oakley A, Thomson NM: A reproducible model of chronic rejection in rat renal allografts. Aust NZ J Surg 1995;65:114–119.
[PubMed]
29.
Stein-Oakley AN, Jablonski P, Tzanidis A, Baxter K, Howden BO, Marshall VC, Thomson NM: Development of chronic injury and nature of interstitial infiltrate in a model of chronic renal allograft rejection. Transplantation 1993;56:1299–1305.
[PubMed]
30.
Tandon V, Botha JF, Banks J, Pontin AR, Pascoe MD, Kahn D: A tale of two kidneys – how long can a kidney transplant wait? Clin Transplant 2000;14:189–192.
[PubMed]
31.
Ojo AO, Wolfe RA, Held PJ, Port FK, Schmouder RL: Delayed graft function: risk factors and implications for renal allograft survival. Transplantation 1997;63:968–974.
[PubMed]
32.
Stratta RJ, Moore PS, Farney AC, Rogers J, Hartmann EL, Reeves-Daniel A, et al: Influence of pulsatile perfusion preservation on outcomes in kidney transplantation from expanded criteria donors. J Am Coll Surg 2007;204:873–884.
[PubMed]
33.
Vaughan MR, Pippin JW, Griffin SV, Krofft R, Fleet M, Haseley L, Shankland SJ: ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo. Kidney Int 2005;68:133–144.
[PubMed]
34.
Eto N, Wada T, Inagi R, Takano H, Shimizu A, Kato H, et al: Podocyte protection by darbepoetin: preservation of the cytoskeleton and nephrin expression. Kidney Int 2007;72:455–463.
[PubMed]
35.
Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T: Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 2006;47:1084–1093.
[PubMed]
36.
Logar CM, Brinkkoetter PT, Krofft RD, Pippin JW, Shankland SJ: Darbepoetin alfa protects podocytes from apoptosis in vitro and in vivo. Kidney Int 2007;72:489–498.
[PubMed]
37.
Marshall CB, Pippin JW, Krofft RD, Shankland SJ: Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. Kidney Int 2006;70:1962–1973.
[PubMed]
38.
Monkawa T, Pippin J, Yo Y, Kopp JB, Alpers CE, Shankland SJ: The cyclin-dependent kinase inhibitor p21 limits murine mesangial proliferative glomerulonephritis. Nephron Exp Nephrol 2005;102:e8–e18.
[PubMed]
39.
Mundel P, Kriz W: Structure and function of podocytes: an update. Anat Embryol (Berl) 1995;192:385–397.
[PubMed]
40.
Pavenstädt H, Kriz W, Kretzler M: Cell biology of the glomerular podocyte. Physiol Rev 2002;83:253–307.
41.
Barisoni L, Kopp JB: Update in podocyte biology: putting one’s best foot forward. Curr Opin Nephrol Hypertens 2003;12:251–258.
[PubMed]
42.
Pätäri-Sampo A, Ihalmo P, Holthöfer H: Molecular basis of the glomerular filtration: nephrin and the emerging protein complex at the podocyte slit diaphragm. Ann Med 2006;38:483–492.
[PubMed]
43.
Kelly DJ, Aaltonen P, Cox AJ, Rumble JR, Langham R, Panagiotopoulos S, et al: Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant 2002;17:1327–1332.
[PubMed]
44.
Luimula P, Ahola H, Wang SX, Solin ML, Aaltonen P, Tikkanen I, et al: Nephrin in experimental glomerular disease. Kidney Int 2000;58:1461–1468.
[PubMed]
45.
Garovic VD, Wagner SJ, Petrovic LM, Gray CE, Hall P, Sugimoto H, et al: Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol Dial Transplant 2007;22:1136–1143.
[PubMed]
46.
Menne J, Meier M, Park JK, Boehne M, Kirsch T, Lindschau C, et al: Nephrin loss in experimental diabetic nephropathy is prevented by deletion of protein kinase C α signaling in-vivo. Kidney Int 2006;70:1456–1462.
[PubMed]
47.
Wiggins RC: The spectrum of podocytopathies: a unifying view of glomerular diseases. Kidney Int 2007;71:1205–1214.
[PubMed]
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2008
You do not currently have access to this content.
